This article is more than 5 years old. Information may no longer be current.

pSivida brings on Deb Jorn as executive vice president of corporate and commercial development

Issue: November 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Deb Jorn has joined pSivida as its executive vice president of corporate and commercial development, according to a company press release.

Jorn, who began her career at Merck and previously worked at Valeant Pharmaceuticals, Bausch + Lomb, Schering-Plough and Johnson & Johnson, will report directly to the company’s President and CEO Nancy Lurker in the newly created position.

Deb Jorn

Jorn will help “establish collaborations leveraging pSivida’s unique technologies” and assist in finalizing an EU partnership deal for pSivida’s Durasert 3-year uveitis treatment, the release said.

“Deb has an impressive track record and her knowledge of the ophthalmology market and her corporate licensing and M&A experience greatly enhance our team’s capabilities,” Lurker said in the release.